Soligenix Awarded Multimillion BARDA Contract for OrbeShield

October 3, 2013
Melanie Sena

Melanie Sena is community editor of Pharmaceutical Technology.

Soligenix has been awarded a multimillion BARDA contract for the advanced preclinical and manufacturing development of OrbeShield, a treatment for gastrointestinal acute radiation syndrome.

Soligenix, a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense medical countermeasures (MCMs), has been awarded a contract valued at up to $26.3 million by the US Department of Health and Human Service’s Biomedical Advanced Research and Development Authority (BARDA). The contract is for the advanced preclinical and manufacturing development of OrbeShield (oral beclomethasone 17,21-dipropionate or oral BDP) as a MCM for the treatment of gastrointestinal acute radiation syndrome (GI ARS).

The potential five-year contract contains a two-year base period, with two contract options that would extend the contract an additional three years. The total award will support the preclinical and manufacturing development activities necessary to navigate and complete the FDA approval process for use of OrbeShield to treat GI ARS.

Source: Soligenix

Related Content:

News